Pivekimab Sunirine shows a 75% complete response rate in BPDCN patients in the CADENZA trial, offering new hope for rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results